291 related articles for article (PubMed ID: 38720734)
21. Liver organoids: a promising three-dimensional model for insights and innovations in tumor progression and precision medicine of liver cancer.
Chen Y; Liu Y; Chen S; Zhang L; Rao J; Lu X; Ma Y
Front Immunol; 2023; 14():1180184. PubMed ID: 37334366
[TBL] [Abstract][Full Text] [Related]
22. Patient-derived organoid culture in epithelial ovarian cancers-Techniques, applications, and future perspectives.
Chan WS; Mo X; Ip PPC; Tse KY
Cancer Med; 2023 Oct; 12(19):19714-19731. PubMed ID: 37776168
[TBL] [Abstract][Full Text] [Related]
23. Exploring Tumor-Immune Interactions in Co-Culture Models of T Cells and Tumor Organoids Derived from Patients.
Jeong SR; Kang M
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834057
[TBL] [Abstract][Full Text] [Related]
24. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy.
Qu J; Kalyani FS; Liu L; Cheng T; Chen L
Cancer Commun (Lond); 2021 Dec; 41(12):1331-1353. PubMed ID: 34713636
[TBL] [Abstract][Full Text] [Related]
25. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM
J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064
[TBL] [Abstract][Full Text] [Related]
26. The applications and techniques of organoids in head and neck cancer therapy.
Qi H; Tan X; Zhang W; Zhou Y; Chen S; Zha D; Wang S; Wen J
Front Oncol; 2023; 13():1191614. PubMed ID: 37427120
[TBL] [Abstract][Full Text] [Related]
27. Organoids and organs-on-chips: insights into predicting the efficacy of systemic treatment in colorectal cancer.
Zhu J; Ji L; Chen Y; Li H; Huang M; Dai Z; Wang J; Xiang D; Fu G; Lei Z; Chu X
Cell Death Discov; 2023 Feb; 9(1):72. PubMed ID: 36813783
[TBL] [Abstract][Full Text] [Related]
28. A Protocol for Organoids from the Urine of Bladder Cancer Patients.
Walz S; Pollehne P; Geng R; Schneider J; Maas M; Aicher WK; Stenzl A; Amend B; Harland N
Cells; 2023 Aug; 12(17):. PubMed ID: 37681920
[TBL] [Abstract][Full Text] [Related]
29. Tumor Organoids: The Era of Personalized Medicine.
Rassomakhina NV; Ryazanova AY; Likhov AR; Bruskin SA; Maloshenok LG; Zherdeva VV
Biochemistry (Mosc); 2024 Jan; 89(Suppl 1):S127-S147. PubMed ID: 38621748
[TBL] [Abstract][Full Text] [Related]
30. Studying the Role of Chromosomal Instability (CIN) in GI Cancers Using Patient-derived Organoids.
Patil S; Jahagirdar S; Khot M; Sengupta K
J Mol Biol; 2022 Feb; 434(3):167256. PubMed ID: 34547328
[TBL] [Abstract][Full Text] [Related]
31. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors.
Cao W; Liu J; Wang L; Li M; Verstegen MMA; Yin Y; Ma B; Chen K; Bolkestein M; Sprengers D; van der Laan LJW; Doukas M; Kwekkeboom J; Smits R; Peppelenbosch MP; Pan Q
Carcinogenesis; 2019 Mar; 40(1):145-154. PubMed ID: 30289434
[TBL] [Abstract][Full Text] [Related]
32. Application Progress of Organoids in Colorectal Cancer.
Luo L; Ma Y; Zheng Y; Su J; Huang G
Front Cell Dev Biol; 2022; 10():815067. PubMed ID: 35273961
[TBL] [Abstract][Full Text] [Related]
33. Bladder Cancer Patient-derived Organoids and Avatars for Personalized Cancer Discovery.
Kim YS; Hsieh AC; Lam HM
Eur Urol Focus; 2022 May; 8(3):657-659. PubMed ID: 35915037
[TBL] [Abstract][Full Text] [Related]
34. Prostate Cancer Organoids for Tumor Modeling and Drug Screening.
Yehya A; Ghamlouche F; Hachem S; Abou-Kheir W
Methods Mol Biol; 2024; 2777():135-144. PubMed ID: 38478341
[TBL] [Abstract][Full Text] [Related]
35. Organoid technology and applications in lung diseases: Models, mechanism research and therapy opportunities.
Chen J; Na F
Front Bioeng Biotechnol; 2022; 10():1066869. PubMed ID: 36568297
[TBL] [Abstract][Full Text] [Related]
36. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
[TBL] [Abstract][Full Text] [Related]
37. Modeling neoplastic disease with spheroids and organoids.
Zanoni M; Cortesi M; Zamagni A; Arienti C; Pignatta S; Tesei A
J Hematol Oncol; 2020 Jul; 13(1):97. PubMed ID: 32677979
[TBL] [Abstract][Full Text] [Related]
38. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
[TBL] [Abstract][Full Text] [Related]
39. Patient-Derived Organoids of Colorectal Cancer: A Useful Tool for Personalized Medicine.
Kiwaki T; Kataoka H
J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629118
[TBL] [Abstract][Full Text] [Related]
40. Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma.
Fang X; Shu L; Chen T; Zhao X; Yang L; Dou T; Yang L; Li X; Feng M
Mol Cancer; 2024 Jan; 23(1):12. PubMed ID: 38200517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
